1. Home
  2. INGN vs GANX Comparison

INGN vs GANX Comparison

Compare INGN & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inogen Inc

INGN

Inogen Inc

HOLD

Current Price

$7.20

Market Cap

186.8M

Sector

Health Care

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.44

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INGN
GANX
Founded
2001
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.8M
159.2M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
INGN
GANX
Price
$7.20
$2.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$11.00
$8.00
AVG Volume (30 Days)
156.7K
2.2M
Earning Date
02-24-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$347,028,000.00
N/A
Revenue This Year
$8.04
N/A
Revenue Next Year
$8.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.68
N/A
52 Week Low
$5.70
$1.41
52 Week High
$12.91
$4.34

Technical Indicators

Market Signals
Indicator
INGN
GANX
Relative Strength Index (RSI) 59.28 38.50
Support Level $6.53 $2.30
Resistance Level $7.46 $3.29
Average True Range (ATR) 0.18 0.48
MACD 0.08 -0.13
Stochastic Oscillator 72.04 19.33

Price Performance

Historical Comparison
INGN
GANX

About INGN Inogen Inc

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: